Hemodiafiltration: clinical, hemodinamic and cardiovascular benefits

Abstract

Several studies in the area of Nephrology have addressed the impact of dialysis treatment in patients with Chronic Renal Insufficiency (CKD). This disease affects the kidneys, which over time lose the ability to filter the toxins from the blood. Comorbidities associated with CKD may also arise, such as bone demineralization, anemia and worsening of arterial hypertension. In addition, common cardiovascular problems in CKD are among the most serious problems faced by the patient on dialysis, as well as those awaiting a kidney transplant. Hemodiafiltration is the latest and most modern form of dialysis because it removes more toxins than in conventional hemodialysis. In this way, results such as reduced rates of inflammation, malnutrition, anemia, as well as cardiovascular risks, such as heart failure. The performance of Hemodiafiltration also presupposes optimizing all other parameters that contribute to the increase in the diffusive and convective capacity of the treatments, such as: vascular access flow, blood circulation velocity and dialysing flow, membrane area enlargement and adequate anticoagulation. The present study aims to verify in the latest literature data on hemodiafiltration modality, verifying its clinical, dynamic and cardiovascular benefits. A literature
review of articles published between 2007 and 2017 was carried out in the electronic databases PubMed Mediline, Scielo and Science Direct. Predetermined descriptors were used in English and Portuguese, covering articles that used "hemodiafiltration", "renal system", "hemodialysis", and "dialysis" used in combination. The bibliographic references of the works identified by the electronic research were reviewed to identify additional studies. Results: This review may show that hemodiafiltration has a better efficacy among the modalities of dialytic therapies, because it approaches the volume of filtration of the healthy kidney.